Recent advances in design of immunogenic and effective naked DNA vaccines against cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 9, Issue 1, 2014, Pages 66-82

  Fioretti, Daniela ^a   Iurescia, Sandra ^a   Rinaldi, Monica ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Cancer; Dna vaccine; Epitope; Genetic adjuvant; Immunotherapy; T cell help; Targeting; Tumour antigens

Indexed keywords

DNA VACCINE; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 6; PLASMID DNA; TOLL LIKE RECEPTOR 9;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DNA IMMUNIZATION; DRUG DESIGN; EPITOPE MAPPING; EXPERIMENTAL DESIGN; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INTRACELLULAR SIGNALING; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOGENETIC PHENOMENA; MOLECULAR SEQUENCE DATA; NEOPLASMS; PATENTS AS TOPIC; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84901249653     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574891x113089990037     Document Type: Review

References (160)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21(2): 137-48.
2. Zhou G, Levitsky H. Towards curative cancer immunotherapy: Overcoming posttherapy tumor escape. Clin Devel Immunol 2012; 2012: 124187.
3. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58(3): 317-24.
4. Raez LE, Fein S, Podack ER. Lung cancer immunotherapy. Clin Med Res 2005; 3(4): 221-8.
5. Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. J Thorac Oncol 2006; 1(1): 93-104.
6. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009; 6(2): 224-32.
7. Dougan M, Dranoff G. Immune therapy for cancer. Ann Rev Immunol 2009; 27: 83-117.
8. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: Which vector for which strategy? Curr Gene Ther 2008; 8(2): 66-78.
9. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: Developing new strategies against cancer. J Biomed Biotechnol 2010; 2010; DOI: 10.1155/2010/174378.
10. Kang TH, Mao CP, La V, Chen A, Hung CF, Wu TC. Innovative DNA vaccine to break immune tolerance against tumor selfantigen. Hum Gene Ther 2013; 24(2): 181-8.
11. Reisfeld RA. The tumor microenvironment: A target for combination therapy of breast cancer. Crit Rev Oncog 2013; 18(1-2): 115-33.
12. Stevenson FK, Mander A, Chudley L, Ottensmeier CH. DNA fusion vaccines enter the clinic. Cancer Immunol Immunother 2011; 60(8): 1147-51.
13. Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006; 91(2): 610-9.
14. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, 2nd, et al. Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev Biol (Basel) 2000; 104: 33-43.
15. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11(8): 711-21.
16. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1- seronegative subjects. J Acquir Immune Defic Syndr 2007; 44(5): 601-5.
17. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005; 55: 25-40.
18. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7(2): 175-91.
19. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24(21): 4475-81.
20. Egan MA, Megati S, Roopchand V, Garcia-Hand D, Luckay A, Chong SY, et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 2006; 24(21): 4510-23.
21. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188(6): 1075-82.
22. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21(25-26): 4036-42.
23. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3(6): 362-71.
24. Torres CA, Iwasaki A, Barber BH, Robinson HL. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 1997; 158(10): 4529-32.
25. Howarth M, Elliott T. The processing of antigens delivered as DNA vaccines. Immunol Rev 2004; 199: 27-39.
26. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165(5): 2850-8.
27. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, et al. Plasmid vaccine expressing granulocytemacrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000; 165(7): 3772-81.
28. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Immunology, application, and optimization*. Annu Rev Immunol 2000; 18: 927-74.
29. Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 2007; 25 Suppl 2: B24-34.
30. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007; 81(10): 5257-69.
31. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Hoglund U, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007; 179(7): 4741-53.
32. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases. Curr Drug Metab 2013; 14(3):279-90.
33. Murtaugh MP, Foss DL. Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunopathol 2002; 87(3-4): 109-21.
34. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008; 82(11): 5643-9.
35. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11(8): 899-904.
36. Quaak SG, van den Berg JH, Toebes M, Schumacher TN, Haanen JB, Beijnen JH, et al. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. Eur J Pharm Biopharm 2008; 70(2): 429-38.
37. Lowe DB, Shearer MH, Jumper CA, Kennedy RC. Towards progress on DNA vaccines for cancer. Cell Mol Life Sci 2007; 64(18): 2391-403.
38. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302(5644): 415-9.
39. Fazio VM, Ria F, Franco E, Rosati P, Cannelli G, Signori E, et al. Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization. Gene Ther 2004; 11(6): 544-51.
40. Rinaldi M, Signori E, Rosati P, Cannelli G, Parrella P, Iannace E, et al. Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: Transgene expression, immunity and safety. Vaccine 2006; 24(21): 4586-91.
41. Jo, E.-C., Koh, D., Lee, H., Lee, K., Yun, S. Expression vector suitable for expression of a coding sequence for gene therapy. US20120282687 (2012).
42. Banes, A.J., Qi, J. Nuclear targeting sequence. US8288511 (2012).
43. Dean, D.A. Methods and compositions for importing nucleic acids into cell nuclei. US7604798 (2009).
44. Essand, M. TARP promoter and uses thereof. US20070032439 (2007).
45. Kay, A.M., Miao, H.C. Liver-specific gene expression cassettes, and methods of use. WO2001098482 (2003).
46. Calenda, V., Frauli, M., Neuville, P., Ribaul, S. Chimeric promoters for controlling expression in skeletal muscle cells. EP1310561 (2003).
47. Dean, D.A. Molecule and method for importing DNA into a nucleus. US5827705 (1998).
48. La Monica, N., Facciabene, A., Aurisicchio, L., Ciliberto, G. Carcinoembryonic antigen fusions and uses thereof. US8188244 (2012) & CN101001869B (2013).
49. Scarselli, E., Mennuni, C., La Monica, N., Ciliberto, G. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof. US8017387 (2011).
50. Sette, A., Chesnut, R., Livingston, B.D., Baker, D.M., Newman, M.J. Method and system for optimizing minigenes and peptides encoded thereby. US7462354 (2008).
51. Wu, T.-C., Hung, C.-F. Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen. US8128922 (2012).
52. Wu, T.-C., Hung, C.-F. Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen. US8007781 (2011) & US20130203961 (2013).
53. Franconi, R., Massa, S., Venuti, A., Spanò, L. Vaccines based on genetic chimera of viral and/or tumoral antigens and vegetable proteins. WO2011010337 (2011).
54. La Monica, N., Scarselli, E., Ciliberto, G., Aurisicchio, L., Fridman, A., Bagchi, A. Minigene. US20110182926 (2011).
55. Jaffee, E., Hruban, R. Mesothelin vaccines and model systems. US8137908 (2012).
56. Gaudernack, G., Sreboe-Larssen, S., Moller, M., Eriksen, J.A. Nucleic acids encoding novel TERT polypeptides. US8193326 (2012).
57. Jakobovits, A., Afar, D.E.H., Challita-Eid, P.M., Levin, E., Chappell, M.S., Hubert, R.S. 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer. US8013126 (2011).
58. Wei, W.-Z., Wu, G.S., Piechocki, M.P., Jones, R.F. Vaccines targeting cellular death receptors. WO2010054156 (2010).
59. Eisenbach, L., Tirosh, B., Bar-Haim, E., Paz, A., Fridkin, M., Fitzer-Attas, C., Machlenkin, A., Tzehoval, E. Tumor associated antigen peptides and use of same as anti-tumor vaccines. US7960507 (2011).
60. Manucharyan, K., Gevorgyan, G. Immunogens for vaccines against antigenically variable pathogens and diseases. US20090214591 (2009).
61. Kutzler, M., Weiner, D.B. Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same. US20120213815 (2012) & JP2013051972 (2013).
62. Chang, W.-F., Chen, C.-A. DNA vaccine comprising IL-6- encoding DNA construct and applications thereof. US20120121715 (2012).
63. Nelson, A.J., Hughes, S.D., Holly, R.D. Methods of treating cancer using IL-21. US20110002882 (2011).
64. Punnonen, J., Lazetic, A., Leong, S.R., Chang, C.-C., Apt, D., Gustafsson, C. Novel co-stimulatory molecules. US20100261660 (2010).
65. Hwu, P., Wang, G., Leonard, W., Spolski, R., Ozaki, K. Method for treating cancer in humans. US20100135958 (2010).
66. Chang, S.-Y., Chung, Y., Kang, C.-Y., Kim, D.-H., Lee, J.Y., Lee, K.-C. Her-2/neu DNA vaccine having anti-cancer activity. EP1539971 (2005).
67. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann Rev Immunol 1997; 15: 617-48.
68. Cazeaux N, Bennasser Y, Vidal PL, Li Z, Paulin D, Bahraoui E. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine 2002; 20(27-28): 3322-31.
69. Cheng WS, Giandomenico V, Pastan I, Essand M. Characterization of the androgen-regulated prostate-specific T cell receptor gammachain alternate reading frame protein (TARP) promoter. Endocrinology 2003; 144(8): 3433-40.
70. Lee K, Yun ST, Kim YG, Yoon Y, Jo EC. Adeno-associated virusmediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology 2006; 43(5): 1063-73.
71. Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, Hong SW, et al. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res 2004; 64(19): 7092-8.
72. Dean DA, Strong DD, Zimmer WE. Nuclear entry of nonviral vectors. Gene Ther 2005; 12(11): 881-90.
73. Rinaldi M, Fioretti D, Iurescia S, Signori E, Pierimarchi P, Seripa D, et al. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochem Biophys Res Commun 2008; 370(2): 279-84.
74. Lam AP, Dean DA. Progress and prospects: Nuclear import of nonviral vectors. Gene Ther 2010; 17(4): 439-47.
75. Degiulio JV, Kaufman CD, Dean DA. The SP-C promoter facilitates alveolar type II epithelial cell-specific plasmid nuclear import and gene expression. Gene Ther 2010; 17(4): 541-9.
76. Qi J, Chi L, Labeit S, Banes AJ. Nuclear localization of the titin Z1Z2Zr domain and role in regulating cell proliferation. Am J Physiol Cell Physiol 2008; 295(4): C975-85.
77. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72(2): 1497-503.
78. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6(3): 315-24.
79. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115(1): 33-42.
80. Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, et al. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther 2009; 17(10): 1804-13.
81. Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol 2007; 8(10): 1041-8.
82. Yewdell JW, Bennink JR. Cut and trim: Generating MHC class I peptide ligands. Curr Opin Immunol 2001; 13(1): 13-8.
83. Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D. DNA fusion gene vaccines against cancer: From the laboratory to the clinic. Immunol Rev 2004; 199: 156-80.
84. Leifert JA, Rodriguez-Carreno MP, Rodriguez F, Whitton JL. Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 2004; 199: 40-53.
85. Marshall RS, D'Avila F, Di Cola A, Traini R, Spano L, Fabbrini MS, et al. Signal peptide-regulated toxicity of a plant ribosomeinactivating protein during cell stress. Plant J 2011; 65(2): 218-29.
86. Delogu G, Li A, Repique C, Collins F, Morris SL. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 2002; 70(1): 292-302.
87. Norbury CC, Princiotta MF, Bacik I, Brutkiewicz RR, Wood P, Elliott T, et al. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol 2001; 166(7): 4355-62.
88. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Ann Rev Immunol 1997; 15: 821-50.
89. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61(9): 3698-703.
90. Mohammed AF, Abdul-Wahid A, Huang EH, Bolewska-Pedyczak E, Cydzik M, Broad AE, et al. The Pseudomonas aeruginosa exotoxin A translocation domain facilitates the routing of CPPprotein cargos to the cytosol of eukaryotic cells. J Control Release 2012; 164(1): 58-64.
91. Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: Can endogenous antigens be targeted? Cancer Prev Res (Phila) 2010; 3(4): 410-5.
92. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev1999; 170: 85-100.
93. Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008; 7(3): 449-54.
94. Caballero OL, Chen YT. Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 2009; 100(11): 2014-21.
95. Disis ML, Cheever MA. HER-2/neu oncogenic protein: Issues in vaccine development. Crit Rev Immunol 1998; 18(1-2): 37-45.
96. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J Clin Oncol 2002; 20(8): 2197-207.
97. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994; 54(12): 3124-6.
98. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91(9): 3515-9.
99. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91(14): 6458-62.
100. Doehn C, Bohmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer vaccines: Current status and future potential. BioDrugs 2008; 22(2): 71-84.
101. George AJ, Stevenson FK. Prospects for the treatment of B cell tumors using idiotypic vaccination. Int Rev Immunol 1989; 4(4): 271-310.
102. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15(17): 5323-37.
103. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas identification of a new pancreatic cancer marker by Serial Analysis of Gene Expression (SAGE). Clin Cancer Res 2001; 7(12): 3862-8.
104. Hassan R, Bera T, Pastan I. Mesothelin: A new target for immunotherapy. Clin Cancer Res 2004; 10(12 Pt 1): 3937-42.
105. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010; 14(10): 1091-108.
106. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16(6): 1701-8.
107. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: First listing. Immunogenetics 1995; 41(4): 178-228.
108. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C, et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci USA 1989; 86(9): 3296-300.
109. Iurescia S, Fioretti D, Fazio VM, Rinaldi M. Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: A biotech's challenge. Biotechnol Adv 2012; 30(1): 372-83.
110. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1(3): 209-19.
111. Borbulevych OY, Baxter TK, Yu Z, Restifo NP, Baker BM. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: Implications for vaccine design. J Immunol 2005; 174(8): 4812-20.
112. Ridman, A., Bagchi, A., Bailey, W. System and method for automated selection of T-cell epitopes. WO2006124408 (2006).
113. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol 1995; 147(5): 1383-97.
114. Raymond A, Ensslin MA, Shur BD. SED1/MFG-E8: A bi-motif protein that orchestrates diverse cellular interactions. J Cell Biochem 2009; 106(6): 957-66.
115. Kufe DW. Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 2009; 9(12): 874-85.
116. Bianco C, Salomon DS. Human Cripto-1 as a target for a cancer vaccine: WO2008040759. Expert Opin Ther Pat 2009; 19(2): 141-4.
117. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152(1): 163-75.
118. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13(4): 529-38.
119. Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 2002; 59(6): 443-51.
120. Zinkernagel RM. Uncertainties - discrepancies in immunology. Immunol Rev 2002; 185: 103-25.
121. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421(6925): 852-6.
122. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19(12): 2237-42.
123. Egan AF, Blackman MJ, Kaslow DC. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun 2000; 68(3): 1418-27.
124. Lee EA, Palmer DR, Flanagan KL, Reece WH, Odhiambo K, Marsh K, et al. Induction of T helper type 1 and 2 responses to 19- kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002; 70(3): 1417-21.
125. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160(4): 1750-8.
126. Iurescia S, Fioretti D, Pierimarchi P, Signori E, Zonfrillo M, Tonon G, et al. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. J Biomed Biotechnol 2010; 2010: 316069.
127. Lund LH, Andersson K, Zuber B, Karlsson A, Engstrom G, Hinkula J, et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 2003; 10(5): 365-76.
128. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J Immunol 2001; 167(3): 1558-65.
129. Iurescia S, Fioretti D, Fazio VM, Rinaldi M. Design and preclinical development of epitope-based DNA vaccines against B-cell lymphoma. Curr Gene Ther 2011; 11(5): 414-22.
130. Pittaluga E, Poma A, Tucci A, Spano L. Expression and characterisation in E. coli of mutant forms of saporin. J Biotechnol 2005; 117(3): 263-6.
131. Paolini F, Massa S, Manni I, Franconi R, Venuti A. Immunotherapy in new pre-clinical models of HPV-associated oral cancers. Hum Vaccin Immunother 2013; 9(3): 1-10.
132. Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: The double-edged sword. Expert Rev Vaccines 2007; 6(2): 267-83.
133. Rinaldi M, Ria F, Parrella P, Signori E, Serra A, Ciafre SA, et al. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of Blymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res 2001; 61(4): 1555-62.
134. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199: 84-99.
135. Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S, et al. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 2005; 5: 1.
136. Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008; 16(12): 2022-9.
137. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27(25): 4047-54.
138. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15(1): 361-7.
139. Nimal S, McCormick AL, Thomas MS, Heath AW. An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming. Vaccine 2005; 23(30): 3984-90.
140. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012; 11(2): 189-209.
141. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10(4): 312-7.
142. Heller R, Cruz Y, Heller LC, Gilbert RA, Jaroszeski MJ. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum Gene Ther 2010; 21(3): 357-62.
143. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7(1): e29231.
144. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448(7152): 480-3.
145. Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleukin-21 signaling: Functions in cancer and autoimmunity. Clin Cancer Res 2007; 13(23): 6926-32.
146. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: Combination strategies for cancer therapy. Nat Rev Drug Discov 2008; 7(3): 231-40.
147. Sumida SM, McKay PF, Truitt DM, Kishko MG, Arthur JC, Seaman MS, et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 2004; 114(9): 1334-42.
148. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15(7): 641-6.
149. Flo J, Tisminetzky S, Baralle F. Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules. Immunology 2000; 100(2): 259-67.
150. Jalah R, Rosati M, Ganneru B, Pilkington GR, Valentin A, Kulkarni V, et al. The p40 subunit of IL-12 promotes stabilization and export of the p35 subunit: Implications for improved IL-12 cytokine production. J Biol Chem 2013 [Epub ahead of print].
151. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B, et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother 2012; 8(11).
152. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/study/NCT01138410. (Accessed on: February 21, 2012).
153. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Strigard K, Eriksson E, Samanci A, et al. Durable carcinoembryonic antigen (CEA)- specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004; 10(10): 3273-81.
154. Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine 2011; 29(39): 6817-22.
155. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/study/NCT01064375. (Accessed on: February 21, 2012).
156. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006; 91(12): 1653-61.
157. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT01334060. (Accessed on: February 21, 2012).
158. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008; 112(7): 2956-64.
159. Clinicaltrials.gov. Available at: http://clinicaltrials.gov/show/NCT00849121. (Accessed on: January 21, 2013).
160. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT01341652?term=DNA+vaccine+AND+prostate+cancer&rank =4. (Accessed on: January 21, 2013).